1. Agenda Change
Need greater clarity on lessons learnt and policy implications
Time too short for working groups
Afternoon plenary session

2. Final session VCT (PNa) IPT (DM/KF) CPT (ADH)
Intensified case-finding (JvG)
TB/HIV programme collaboration (PGF)
ARVs (PN)
Summary of lessons learnt
Recommendations for future actions
Information still needed:
Underway in ProTEST
Available elsewhere
Not available/not coming

3. Expansion and ARVs Lessons learnt Recommendations
TB/HIV collaboration offers a way
Demand and need
TB/HIV WG and STAG expand
District/national scale
ARVs driving HIV care agenda
Recommendations
Link with district scale ARV programmes
Advocate, encourage, stimulate, foster, assist etc. ARV delivery - Engage
Ensure TB patients access ARVs
Ensure ARV-seeking TB suspects access TB care

4. Need to know: the structure
VCT/TC
PMTCT+/-
TB Clinic
(? +TC)
Start ARVs
Post TB Rx ARV management
Immune reconstitution TB
Monitor during ARV treatment
HIV/AIDS
ARV Clinic
OPD
GeneralWards

5. Still need to know Treatment issues:
What ARV regimens can safely be used with anti-TB Rx? (Clinical trials - coming)
Should we use rifabutine? (No)
When is the best point to start ARVs during anti-TB Rx? (Starting - need more studies)
Operational issues: human resources, funds, structures, processes, etc (Coming, needs further planning)

6. Next steps
Continued TB/HIV programme collaboration - global to community
Garner information from countries, especially on ARVs, eg WHO “toolkit”
Meeting report
Interim policy
Wide consultation - ProTEST and non-ProTEST
Writing group